MAR-APREMILAST TABLET
国: カナダ
言語: 英語
ソース: Health Canada
製品の特徴
(SPC)
22-06-2022
この製品の一部のドキュメントは現在利用できません。カスタマーサービスにリクエストを送信できます。入手可能になり次第、お知らせします。
リクエストを送信します。
リクエストを送信します。
有効成分:
APREMILAST; APREMILAST; APREMILAST
から入手可能:
MARCAN PHARMACEUTICALS INC
ATCコード:
L04AA32
INN（国際名）:
APREMILAST
投薬量:
10MG; 20MG; 30MG
医薬品形態:
TABLET
構図:
APREMILAST 10MG; APREMILAST 20MG; APREMILAST 30MG
投与経路:
ORAL
パッケージ内のユニット:
100
処方タイプ:
Prescription
製品概要:
Active ingredient group (AIG) number: 0356230001; AHFS:
認証ステータス:
APPROVED
承認日:
2022-11-14
製品の特徴
_Page 1 of 35 _
PRODUCT MONOGRAPH
PR
MAR-APREMILAST
apremilast tablets
10 mg, 20 mg, and 30 mg
Selective Immunosuppressant
MARCAN PHARMACEUTICALS INC.
2 Gurdwara Road, Suite #112,
Ottawa, ON, K2E 1A2
SUBMISSION CONTROL NO.: 246219
DATE OF PREPARATION:
June 22, 2022
_Page 2 of 35 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
................................................................ 3
SUMMARY PRODUCT INFORMATION
....................................................................................
3
INDICATIONS AND CLINICAL USE
..........................................................................................
3
CONTRAINDICATIONS
...........................................................................................................
4
WARNINGS AND PRECAUTIONS
...........................................................................................
4
ADVERSE REACTIONS
...........................................................................................................
6
DRUG INTERACTIONS
.........................................................................................................
11
DOSAGE AND ADMINISTRATION
.........................................................................................
13
OVERDOSAGE
.....................................................................................................................
14
ACTION AND CLINICAL
PHARMACOLOGY...........................................................................
14
STORAGE AND STABILITY
...................................................................................................
17
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................................... 17
PART II: SCIENTIFIC INFORMATION
...................................................................................
18
PHARMACEUTICAL INFORMATION
.....................................................................................
18
CLINICAL TRIALS
.............................................................
完全なドキュメントを読む
